APLS241115C23000
- 3.70
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
Apellis Pharmaceuticals Analyst Ratings
UBS Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $45
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $55
Earnings Call: Apellis Pharmaceuticals Q3 2024 Results Show Promise
RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $24
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals Price Target Cut to $30.00/Share From $43.00 by Wells Fargo
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $40 From $65, Maintains Outperform Rating
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $75
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Apellis Pharmaceuticals Is Maintained at Buy by B of A Securities
Apellis Pharmaceuticals (APLS) Receives a Hold From Piper Sandler
Strategic Positioning and Strong Efficacy Drive 'Buy' Rating for Apellis Pharmaceuticals
Apellis Pharmaceuticals: Hold Rating Amid Revenue Miss and Financial Challenges
Apellis Pharmaceuticals Reports Revenue Growth Amid Ongoing Investments
Express News | Apellis Pharmaceuticals Inc : Piper Sandler Cuts Target Price to $32 From $40
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript Summary